Erschienen in:
01.12.2012 | Editorial
Is there a role for fluorine-18 fluorodeoxyglucose positron emission tomography imaging in medullary thyroid cancer?
verfasst von:
Saila Kauhanen, Camilla Schalin-Jäntti
Erschienen in:
Endocrine
|
Ausgabe 3/2012
Einloggen, um Zugang zu erhalten
Excerpt
Medullary thyroid cancer (MTC) is an uncommon and challenging malignancy. In spite of aggressive primary treatment with total thyroidectomy and modified neck lymph node dissection, approximately 50 % of the patients have persistent or recurrent disease [
1,
2]. The recent European Thyroid Association guidelines [
3] recommend surgery and other local treatment modalities (such as external beam radiation therapy, radiofrequency ablation, and chemoembolization) for the treatment of distant metastases in patients with low tumor burden (distant metastases limited to single organ) and stable disease, while patients with symptoms, significant tumor burden and progressive disease should receive novel targeted systemic therapies. However, imaging of recurrent disease in MTC is difficult and still poses a major problem in the management of the disease. …